ReviewDiabetology & metabolic syndrome2026
The effect of olanzapine on diabetes related index in humans: a systematic review and meta-analysis of randomized controlled trials.
Review in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimOlanzapine is a widely used second-generation antipsychotic with well-established efficacy in the treatment of schizophrenia, bipolar disorder, and related psychiatric conditions. However, its use has been consistently linked to metabolic adverse effects, particularly disturbances in glucose regulation. This systematic review and meta-analysis aimed to quantitatively evaluate the effects of olanzapine on key diabetes-related biomarkers, fasting blood sugar (FBS), fasting insulin, and glycated hemoglobin (HbA1c), in human populations, using evidence derived exclusively from randomized controlled trials (RCTs).
methodsA comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and Embase from inception to July 1, 2025, without language or date restrictions. Eligible studies were RCTs involving human participants that compared olanzapine with placebo or no treatment and reported pre- and post-intervention data for FBS, fasting insulin, or HbA1c. Study quality was assessed using the Cochrane Risk of Bias 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Pooled effect estimates were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using random-effects models. Subgroup, sensitivity, and publication bias analyses were performed to explore heterogeneity and assess result robustness.
resultsFifteen RCTs comprising 18 comparison arms were included in the meta-analysis. Olanzapine treatment was associated with a statistically significant increase in FBS (WMD: 2.618 mg/dL; 95% CI: 0.283 to 4.954) and fasting insulin levels (WMD: 3.636 µIU/mL; 95% CI: 1.964 to 5.307). In contrast, no significant change was observed in HbA1c levels (WMD: -0.029%; 95% CI: -0.284 to 0.226). Subgroup analyses suggested larger glycemic changes with higher doses (≥ 10 mg/day), longer treatment durations (≥ 12 weeks), and lower baseline body mass index, although these trends were not consistently statistically significant. Substantial heterogeneity was observed for FBS outcomes, whereas fasting insulin results were highly consistent across studies.
conclusionOlanzapine use is associated with modest but significant elevations in FBS and insulin levels, indicating early disturbances in glucose homeostasis and a potential risk of insulin resistance, while effects on HbA1c remain inconclusive. Clinically, this highlights the need for routine monitoring of glucose and insulin levels, early lifestyle interventions, and consideration of pharmacologic strategies in high-risk patients to prevent progression to diabetes. These findings underscore the importance of proactive metabolic monitoring and individualized risk assessment in patients receiving olanzapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.